Answers are grounded in this paper and cite their sources.
e19000 Background: The POLARIX trial established polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) as a potential new standard of care for previously untreated intermediate- and high-risk DLBCL, demonstrating a significant 5-year progression-free survival benefit over rituximab, cyclophosphamide, doxorubicin, oncovorin, and prednisone (R-CHOP), with similar overall survival and safety profiles. However, the generalizability of these trial findings to diverse patient populations and routine clinical practice remains to be fully elucidated. Methods: We conducted a retrospective propensity score-matched (PSM) study using the TriNetX Global Collaborative Network database. We identified adults (≥18 years) with DLBCL/high-grade lymphoma (ICD-10: C83.3) who received either Pola-R-CHP (n=1,045) or R-CHOP (n=18,382). We applied 1:1 PSM for age, sex, race, comorbidities, and transplantation status. The primary outcome was all-cause mortality. Secondary outcomes included hematologic toxicities, infections, cardiomyopathy, and healthcare utilization. Hazard ratios (HR) were calculated with 95% confidence intervals (95% CI), and Kaplan–Meier survival curves were generated. Results: Median follow-up was 347 days for Pola-R-CHP and 365 days for R-CHOP after PSM for demographics, comorbidities, and baseline disease characteristics. After matching, 1,045 patients were included in each cohort. At the 1-year median follow-up, the Pola-R-CHP cohort had a lower all-cause mortality than the R-CHOP cohort (7.0% vs. 13.3%; HR 0.595, 95% CI 0.445–0.794, P<0.001). Kaplan-Meier analysis also showed the survival benefits of Pola-R-CHP. Neutropenia was lower with Pola-R-CHP than with R-CHOP (31.1% vs. 37.5%; P = 0.05), as was the rate of thrombocytopenia (13.2% vs. 16.3%; P = 0.068), but neither reached statistical significance. Peripheral neuropathy was higher with Pola-R-CHP than with R-CHOP (22.2% vs. 19.1%; HR 1.28, 95% CI: 1.049 –1.571, p=0.015). No statistically significant between-groups differences were observed in cardiomyopathy, hospitalization rates, emergency room visits, disease progression, anemia, sepsis, or pneumonia. Conclusions: This real-world PSM study demonstrated significantly reduced all-cause mortality in Pola-R-CHP vs. R-CHOP. While many toxicities were similar, Pola-R-CHP showed a higher rate of peripheral neuropathy. These findings suggest that Pola-R-CHP is a better upfront option with improved survival benefits and no new safety concerns in patients with DLBCL.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: